China Resources Zizhu tiene una línea de producción de medicamentos e instrumentos para la salud reproductiva, así como para medicamentos orales, medicamentos oftalmológicos, medicamentos para la diabetes, medicamentos de anestesia local, api química, etc. En cuanto al mercado nacional, la píldora anticonceptiva de emergencia (Comprimidos de Levonorgestrel) y el medicamento contra el embarazo precoz (Comprimidos de Mifepristona) ocupan la mayor proporción en el mercado chino, y sus comprimidos de levonorgestrelson es la marca líder de venta de medicamentos en la plataforma O2O del comercio electrónico en los últimos años. En el mercado internacional, China Resources Zizhu ha conseguido la certificación PQ de la Organización Mundial de la Salud y la certificación GMP de WHO Y PICs. Es un proveedor de medicamentos de salud reproductiva para las Naciones Unidas y las principales organizaciones internacionales, y su Levonorgestrel api ha sido pionero en cuento a la cuota en el mercado de exportación, y las exportaciones de comprimidos de Mifepristona y Misoprostol también se cuentan entre los primeros en China. Cumpliendo con el propósito corporativo de "China saludable, Vida mejor", la empresa aumenta constantemente la inversión en la investigción y el desarrollo, enfocándose en la innovación científica y tecnológica, arando profundamente el campo de la salud reproductiva, especialidades especiales y negocios internacionales para buscar la excelencia y perseguir el espíritu de ingeniosidad, ¡y se esfuerza por abrir un nuevo capítulo en el desarrollo a pasos agigantados!
1969
Establishment
In the 1960s and 1970s, Beijing No.3 Pharmaceutical Factory, the predecessor of the company initiated the development of 18-methylnorgestrel, a critical API used for contraceptives and became the first national approved manufacturer of this API a year later. The success of this project filled the gap of oral contraceptive API in China, had epoch-making significance, opened a new chapter for China's industry, and won the "National Science Congress Award" in March 1978.
1996
Relocation
To meet the requirements of urban planning, the manufacture site is relocated to current address, No. 27 Chaoyang North Road, Chaoyang District, Beijing, China. The production in the new manufacture site started on 1 March 1996.
2000
Restructuring
Beijing No. 3 Pharmaceutical Factory was restructured into Beijing Zizhu Pharmaceutical Company Limited in 2000, entering a new stage. The restructuring was in accordance with the State Council's policy on debt-to-equity conversion of partial state-owned enterprises, and approved by the State Economic and Trade Commission and the Beijing Municipal Economic Commission.
2008
API production base
The API production base in Qinhuangdao was built in 2008 based on international development strategical need and Beijing industrial development plan, which guarantees the reliability of API sources for company’s finished products.
2013
Joining CR
The company officially changed its name to China Resources Zizhu Pharmaceutical Co., Ltd. and has become a wholly owned subsidiary of China Resources Pharmaceutical Group since then, entering a brand new stage of development.
2015
Takeover of United Pharmaceutical
Beijing United Pharmaceutical completed the resumption of production and related GMP certification under CRZP’s guidance. The Class II new drug Epalrestat API and finished product were successfully marketed, becoming a billion-dollar variety for CRZP and injecting new momentum into the specialty area.
2021
Green Factory Award
CRZP was selected as a National Green Factory during the event organized by the Ministry of Industry and Information Technology, aiming at implementing "Made in China 2025" and "Industrial Green Development Plan", accelerating the construction of green manufacturing system and creating advanced models of green manufacturing enterprises.
2022
Current
Committing to human life and health industry, CRZP develops, manufactures and markets pharmaceuticals and health products revolving around female health, characteristic specialties, APIs and international business.
2019.11
2019.11
WHO GMP
Co-package of Mifepristone Tablets and Misoprostol Tablets
2018.12
2018.12
EU GMP
Levonorgestrel API
2018.10
2018.10
EDQM GMP
Levonorgestrel API
2016.10
2016.10
PIC/S GMP
Misoprostol Tablets and Mifepristone （200mg）Tablets
2016.09
2016.09
Mexico COFEPRIS
Misoprostol Tablets
2016.01
2016.01
WHO GMP
Misoprostol Tablets and Mifepristone （200mg）Tablets
2013.09
2013.09
Mexico COFEPRIS
Levonorgestrel,Mifepristone,Ethinyl Estradiol API
2012.05
2012.05
WHO GMP
Levonorgestrel,Mifepristone,Ethinyl Estradiol API